be administered to participants via a smartphone application four times daily during 20 days.
37
Assessments will be performed before treatment shift and repeated after 12.5 weeks on Plenadren®.
38
The study will identify the best suited outcome for future randomized clinical trials, and in addition, 
Strength and limitations

49
• The study employs a novel and innovative measurement technology applicable to many 50 other patient groups
51
• The study will become the first to provide an outcome for assessing diurnal variations of mg hydrocortisone per day is recommended [1, 2] . Usually the replacement regimen is divided into 70 2 to 3 daily doses with a higher dose upon waking and the smallest dose in the afternoon/evening, in 71 an attempt to mimic the physiological rhythm of cortisol [3] [4] [5] [6] . Despite optimized regimens, it has, 72 however, been clear to most clinicians that this replacement regimen is far from optimal in terms of 73 many factors including mortality and important aspects of quality of life (QoL) such as fatigue [4, 7, 74 8]. Hydrocortisone has a short plasma half-life of 1.7 hours, often resulting in undetectable levels in 75 the morning and a steep rise after the first dose, followed by very low levels by mid-afternoon.
76
Thus, patients treated with the conventional replacement regimen characteristically have higher 77 fatigue level at certain times during the day. A possible explanation is the suboptimal imitation of 78 the physiological rhythm. Patients often report sleep disturbances, daytime fatigue, and early 79 morning fatigue associated with inability to undertake employment [4] .
80
To mimic the physiological cortisol rhythm more closely a dual-release formulation of 81 hydrocortisone, Plenadren®, was developed. It has been shown to significantly improve QoL, 82 particularly fatigue, when measured as secondary outcomes of a recent clinical trial in patients with 83 primary adrenal insufficiency [9] . However, it is unknown, if a similar effect can be observed in 84 patients with secondary adrenal insufficiency due to hypopituitarism. Furthermore, no studies have 85 evaluated the effect, taking into account the diurnal variation of fatigue. 
Methods and analysis
102
Design
103
The PlenadrEMA study is an investigator-initiated open-label cross-over pilot trial. Included 104 patients will be observed for 5 weeks on their usual treatment (twice or thrice daily hydrocortisone).
105
Assessments of QoL, in terms of EMA assessments, to be used as baseline measurement in the 106 study, will be collected for 20 days preceded by a 5 days technology adaptation phase (see Figure   107 1). Thereafter participants will be shifted to dual-release hydrocortisone (Plenadren®) once daily, as primary outcome will be performed 12.5 weeks after initiation of the intervention treatment, in 110 order to take into consideration the period of re-adjustment of the body after the switch from 111 conventional hydrocortisone to Plenadren®. As done at the baseline observation, 20 days of EMA 112 measurements will be preceded by a five days technology adaptation phase. At the end of the 113 intervention treatment period, the patients will be shifted to their usual hydrocortisone treatment and 114 will be followed at the outpatient clinic according to the standard directives of the clinic.
115
Study population
116
All patients with a diagnosis of adrenal insufficiency due to hypopituitarism who are referred to or 
126
Exclusion criteria: Pregnancy; breast feeding; acromegaly; Cushing's disease; diabetes mellitus; 127 other major confounding disease; known or expected hypersensitivity to any of the excipients; lack 128 of compliance (attendance and medication).
129
Given that the method of EMA measurement of fatigue is novel, power calculations to determine 130 the correct sample size cannot be conducted on a sufficiently informed basis, since the magnitude of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   7 the expected change and the variability is unknown. In order to obtain reliable estimates of 132 variability and magnitude of expected differences, a sample-size of N=30 was decided for this pilot 133 study.
134
Intervention
135
The investigational medicinal product in this study is the dual-release hydrocortisone, Plenadren®.
136
It is produced and delivered by Shire in tablets containing 5 mg and 20 mg hydrocortisone, and will 137 be stored according to Summary of Product Characteristics. The initial dose of Plenadren® is equal 138 to the total daily dose of the patients' usual conventional hydrocortisone. Patients will be instructed 139 to take the Plenadren® tablets orally in fasting state in the morning (between 6.00-8.00 AM). The 140 duration of the intervention period is 16 weeks, including a run-in period of 12.5 weeks.
141
The usual hydrocortisone replacement regimen of the patients, i.e. conventional hydrocortisone, is 
Collection of EMA data
148
In our research group, we have developed a smartphone application for collection of EMA data [11] .
149
It follows state-of-the-art standards for electronic EMA instruments as described in the field of to delay a data entry for up to one hour, and time stamping of data-entries in order to evaluate 152 compliance. The EMA application is integrated with the trial management system PROgmatic [13] .
153
The integrated system handles patient-flow, electronic case report forms and collection of EMA Outcome measures 160 The primary outcome of the study is variability and difference in fatigue between conventional and 
168
The reason for administrating only one of the four specific scales per day is to reduce response 169 burden; thus, these scales are administered in cycles of four days: Physical Fatigue on day one,
170
Mental Fatigue on day two, Reduced Activity on day three and Reduced Motivation on day four.
171
Secondary outcome assessment is specified in Table 1 
185
EMA: Ecological momentary assessment; QoL: Quality of life; DEXA: Dual-energy X-ray absorptiometry.
186
Biobank
187
A research biobank of serum and plasma will be established for analysis of biochemical markers Protections Agency.
194
Monitoring
195
The trial will be monitored by the Good Clinical Practice unit at Copenhagen University Hospital.
196
Data and statistical analysis 197
For each of the two EMA reporting periods, four diurnal fatigue profiles are generated for each vs. dual-release hydrocortisone, will be evaluated by mixed models for repeated measures. All 203 analyses will be conducted as intention-to-treat analyses, with two-sided significance level at 5%.
204
Patient safety and adverse event recording
205
Participants are questioned about adverse events (AEs) according to Ethics and dissemination
219
The study protocol is approved by the Regional Scientific Ethical Committee in Copenhagen hydrocortisone, specific follow-up for dropouts and patients withdrawn from the trial are not 240 required.
241
The results of this study will be presented at national and international conferences as well as to 242 patients and clinicians. Results will be submitted for publication in peer-reviewed journals. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Funding
335
The project is an investigator-initiated pilot study emanated from the Department of Medical 
36
37
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Strength and limitations
50
• The study employs a novel and innovative measurement technology applicable to many 51 other patient groups
52
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107
Assessments of QoL, in terms of EMA assessments, to be used as baseline measurement in the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 the intervention treatment period, the patients will be shifted to their usual hydrocortisone treatment 117 and will be followed at the outpatient clinic according to the standard directives of the clinic.
118
Study population
119
All patients with a diagnosis of adrenal insufficiency due to hypopituitarism who are referred to or 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
of compliance (attendance and medication).
132
Given that the method of EMA measurement of fatigue is novel, power calculations to determine 133 the correct sample size cannot be conducted on a sufficiently informed basis, since the magnitude of 134 the expected change and the variability is unknown. In order to obtain reliable estimates of 135 variability and magnitude of expected differences, a sample-size of N=30 was decided for this pilot 136 study, after discussion with an experienced biostatistician. Several other pilot studies have 137 investigated EMA for measuring symptoms. These studies have included between 19 and 33 138 participants [11] [12] [13] [14] [15] [16] , which corresponds well with our chosen sample size.
139
Intervention
140
141
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In our research group, we have developed a smartphone application for collection of EMA data. It 154 follows state-of-the-art standards for electronic EMA instruments as described in the field of EMA- The reason for administrating only one of the four specific scales per day is to reduce response 174 burden; thus, these scales are administered in cycles of four days: Physical Fatigue on day one,
175
176
193
Biobank
194
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